Ukraine Advances Review of Entolimod, Potentially Paving the Way for First National Registration
Market Chameleon (Fri, 14-Aug 7:59 AM ET)
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
ACCESS Newswire (Thu, 13-Aug 10:00 AM ET)
Market Chameleon (Wed, 12-Aug 6:28 AM ET)
ACCESS Newswire (Wed, 12-Aug 9:31 AM ET)
PRNewswire (Wed, 22-Jul 7:45 AM ET)
PRNewswire (Mon, 20-Jul 1:29 PM ET)
PRNewswire (Tue, 14-Jul 7:45 AM ET)
PRNewswire (Thu, 25-Jun 7:45 AM ET)
PRNewswire (Thu, 11-Jun 7:45 AM ET)
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Valion Bio trades on the NASDAQ stock market under the symbol VBIO.
As of August 21, 2026, VBIO stock price was flat at $0.12 with 3,101,462 million shares trading.
VBIO has a beta of 1.47, meaning it tends to be more sensitive to market movements. VBIO has a correlation of 0.02 to the broad based SPY ETF.
VBIO has a market cap of $508,944.00. This is considered a Sub-Micro Cap stock.
VBIO support price is $.10 and resistance is $.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VBIO shares will trade within this expected range on the day.
